

Reference List

1. Pulmonary Embolism Prevention (PEP) trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. *Lancet*. 2000;355:1295-1302.
2. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133:381s-453s.
3. Kleinbart J, Williams MV, Rask K. Prevention of venous thromboembolism. In: Shojania KG, Duncan BW, McDonald KM, et al, eds. In: *Evidence Report/Technology Assessment: Number 43: Making Health Care Safer: A Critical Analysis of Patient Safety Practices*. San Francisco, CA: University of California at San Francisco-Stanford Evidence-Based Practice Center; 2001:333-348. Available at: <http://archive.ahrq.gov/research/findings/evidence-based-reports/services/quality/er43/ptsafety-evidence-report.pdf>. Accessed August 11, 2009.
4. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. *JAMA*. 2003;290:1868-1874.
5. Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. *Br J Surg*. 1991;78:849-852.
6. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? *J R Soc Med*. 1989;82:203-205.
7. Budnitz DS, Pollock DA, Weidenbach KN, et al. National surveillance of emergency department visits for outpatient adverse drug events. *JAMA*. 2006;296:1858-1866.
8. Gould M, Garcia DA, Wren SM, et al. Prevention of VTE in Nonorthopedic Surgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 suppl):e227s-277s.
9. Rosendaal FR. Venous thrombosis: a multicausal disease. *Lancet*. 1999;353:1167-1173.
10. Caprini JA, Arcelus JI, Hasty JH, et al. Clinical assessment of venous thromboembolic risk in surgical patients. *Semin Thromb Hemost*. 1991;17:304-312.
11. Pannucci CJ, Bailey SH, Dreszer G, et al. Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients. *J Am Coll Surg*. 2011;2121:105-112.
12. Bahl V, Hu HM, Henke PK, et al. A validation study of a retrospective venous thromboembolism risk scoring method. *Ann Surg*. 2010;2512:344-350.
13. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. *Chest*. 1995;108:978-981.

14. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. *Ann Surg*. 2006;243:89-95.
15. Mismetti P, Laporte S, Darmon JY, et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. *Br J Surg*. 2001;88:913-930.
16. Michota F. Controversies and new directions in the management of venous thromboembolism in the perioperative setting. *Hospitalist*. 2004;6:s32-s38.
17. Centers for Medicare and Medicaid Services. CMS Improves patient safety for medicare and Medicaid by addressing never events [press release]. Available at: <http://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-Sheets/2008-Fact-Sheets-Items/2008-08-042.html>. Baltimore, MD; August 4, 2008.
18. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. *Thromb Haemost*. 2003;90:446-455.
19. Alcalay A, Wun T, Khatri V, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. *J Clin Oncol*. 2006;24:1112-1118.
20. Marigiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. *Cochrane Database Syst Rev*. 2000:CD001484.
21. Sachdeva A, Dalton M, Amaragiri SV, et al. Elastic compression stockings for prevention of deep vein thrombosis. *Cochrane Database Syst Rev*. 2010;CD001484.
22. Handoll HH, Farrar MJ, McBirnie J, et al. Heparin, low-molecular-weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. *Cochrane Database Syst Rev*. 2002:CD000305.
23. Stewart D, Zalamea N, Waxman K, et al. A prospective study of nurse and patient education on compliance with sequential compression devices. *Am Surg*. 2006;72:921-923.
24. Dennis M, Sandercock PA, Reid J, et al; CLOTS Trials Collaboration. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. *Lancet*. 2009;6;373:1958-1965.
25. Brady D, Raingruber B, Peterson J, et al. The use of knee-length versus thigh-length compression stockings and sequential compression devices. *Crit Care Nurs Q*. 2007;30:255-262.
26. Perez JV, Warwick DJ, Case CP, Bannister GC. Death after proximal femoral fracture-an autopsy study. *Injury*. 1995;26:237-240.
27. Freedman KB, Brookenthal KR, Fitzgerald RH, Jr, et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. *J Bone Joint Surg*. 2000; 82-A:929-938.

28. Y Falck-Ytter, Francis CW, MD; Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141:e278S-e325S
29. American Academy of Orthopaedic Surgeons. Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty Evidence-Based Guideline and Evidence Report. AAOS Web site. Available at: http://www.aaos.org/research/guidelines/VTE/VTE_full_guideline.pdf. Published 2011. Accessed October 31, 2014.
30. Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. *Thromb Haemost*. 2010;103:572-585.
31. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate vs. enoxaparin for prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. *J Thrombosis Haemost*. 2007; 5:2178-2185.
32. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. *Lancet*. 2007;370:949-956.
33. Ginsberg JS, Davidson BL, Comp PC, et al; The RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. *J Arthroplasty*. 2009;24:1-9.
34. Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. *Thromb Haemost*. 2009;101:77-85.
35. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *N Engl J Med*. 2008;358:2776-2786.
36. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *N Engl J Med*. 2008;358:2765-2775.
37. Lassen MR, Raskob GE, Gallus A; the ADVANCE-2 investigators, et al; Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. *Lancet*. 2010;375:807-815.
38. Lassen MR, Raskob GE, Gallus A; ADVANCE-2 investigators, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. *N Engl J Med*. 2010;363:2487-2498.
39. Locke C, Moreland C. Venous thromboembolism prophylaxis in total knee arthroplasty and total hip arthroplasty. *Hosp Med Clin*. 2013;2:e91-e102.

40. Agnelli G, Bergqvist D, Cohen AT, et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. *Br J Surg*. 2005;92:1212-1220.
41. Bergqvist D, Agnelli G, Cohen AT, et al; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. *N Engl J Med*. 2002;346:975-980.
42. Bergqvist D, Burmark US, Flordal PA, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients. *Br J Surg*. 1995; 82:496-501.
43. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. *N Engl J Med*. 1998;339:80-85.
44. Horlocker TT. What's a nice patient like you doing with a complication like this? Diagnosis, prognosis and prevention of spinal hematoma. *Can J Anaesth*. 2004;51:527-534.
45. Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). *Reg Anesth Pain Med*. 2010;35:64-101.
46. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. *J Thromb Haemost*. 2006;4:2384-2390.
47. The National Institute for Health and Care Excellence. Venous thromboembolism: reducing the risk. National Institute for Health and Care Excellence Web site. Available at: <http://guidance.nice.org.uk/CG92>. Published January 2010. Accessed July 22, 2011.
48. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty. *Ann Int Med*. 2001;135:858-869.
49. Eriksson BI, Lassen MR. Duration of prophylaxis against VTE with fondaparinux (2.5 mg sc) after hip-fracture surgery. *Arch Int Med*. 2003;163:1337-1342.
50. Kakkar AK, Brenner B, Dahl DO. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. *Lancet*. 2008;372:31-39.
51. White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. *Arch Intern Med*. 1998;158:1525-1531.

52. Nieto JA. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thromboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials. *Thromb Res*. 2012 Aug;130(2):183-91. PMID: 22425218.

53. Anderson DR. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. *N Engl J Med*. 2018 Feb 22;378(8):699-707. PMID: 29466159. 54. Horlocker TT. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). *Reg Anesth Pain Med*. 2018;43(3):263-309. PMID: 29561531.

